Table 7.
Disposition of topically applied AmB from formulations following permeation experiment using healthy and L. major infected mouse skin.
| Applied Formulations | After 24 h | % AmB Recovered of (Mean ± SD) | ||
|---|---|---|---|---|
| Uninfected Skin | L. major Infected Skin | p-Value t-Test Comparing Infected and Uninfected | ||
| AmB solution | on skin | 94.65 ± 2 | 92.32 ± 1 | >0.05 |
| in skin | 5.35 ± 0.2 | 7.68 ± 0.2 | >0.05 | |
| through skin | 0 | 0 | >0.05 | |
| AmB-CH-TPP nanoparticles | on skin | 69.92 ± 1 | 61.49 ± 1 | <0.05 |
| in skin | 29.85 ± 1 | 38.09 ± 0.5 | <0.05 | |
| through skin | 0.23 ± 0.02 | 0.42 ± 0.05 | <0.05 | |
| AmB-CH-Dex nanoparticles | on skin | 81.65 ± 2 | 73.14 ± 2 | <0.05 |
| in skin | 18.23 ± 1 | 26.58 ± 1 | <0.05 | |
| through skin | 0.12 ± 0.02 | 0.28 ± 0.02 | <0.05 | |
The amounts of AmB recovered from the different sites were expressed as a fraction of the applied amount. The average (± SD) percent for 5 infected mice is shown. p-values were determined by at test comparing uninfected and infected skin. AmB on skin detected in wash and cotton swab, AmB in skin extracted from skin homogenate and AmB through skin detected in receptor fluid. AmB-CH-TPP nanoparticles (Size = 65 ± 8 nm, Zeta potential = 25.5 ± 1 mV) or AmB-CH-Dex nanoparticles (Size = 170 ± 8 nm, Zeta potential = −13 ± 1 mV).